Janssen Pharmaceuticals Inc.

06/12/2021 | Press release | Distributed by Public on 06/12/2021 06:57

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX® (daratumumab) in Patients with Newly Diagnosed[...]